Rheumatoid arthritis

Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital

Rheumatology (Oxford)Published Cross-sectional study

Authors' conclusion

Low socioeconomic status, diabetes, interstitial lung disease and absence of combination with methotrexate allow identification of D2TRA.

Study context

Population
Consecutive RA patients treated at Cochin Hospital, France
Participants
320 consecutive RA patients
Exposure
Difficult-to-treat rheumatoid arthritis (D2TRA) vs non-D2TRA, by EULAR and Alternative definitions
  • EULAR-D2TRAn = 76
  • non-DTRA (EULAR)n = 244reference
  • Alternative D2TRAn = 120
  • non-DTRA (Alternative)n = 200reference
Outcome
Features of D2TRA vs non-D2TRA (both definitions)
Methodological detailssingle-centre, consecutive patients
  • Single-centre
  • Consecutive patients

Main finding

As reported in the abstract

  • Compared with non-D2TRA, D2TRA patients from both definitions more likely to have lower socioeconomic level, positive RF, ILD, higher DAS28-CRP, and more likely to respond to RTX and JAKi
  • EULAR and Alternative D2TRA displayed similar clinical and biological features but different therapeutic profiles

Observational data: associations, not effects.

Further findings

OutcomeEULAR-D2TRAAlternative D2TRAP value
Patients receiving MTXAlternative D2TRA vs EULAR-D2TRA64%53%P = 0.046
  • Patients receiving MTX: comparator of 64% not explicitly named in the abstract

Alternative D2TRA not fulfilling EULAR definition

All had received two successive first-line TNFi (a monoclonal antibody and a soluble receptor); comparable to EULAR-D2TRA in all other characteristics
n = 44

Original publication

Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital. Rheumatology (Oxford). Published 24 March 2023. doi:10.1093/rheumatology/kead143

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.